iodine and Weight Gain
iodine has been researched along with Weight Gain in 29 studies
Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.
diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..
Weight Gain: Increase in BODY WEIGHT over existing weight.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "A farm trial was conducted to evaluate the effect of in-water iodine on piglet growth, the incidence of diarrhea, and the development of deleterious oral and dental conditions." | 9.15 | Effect of in-water iodine supplementation on weight gain, diarrhea and oral and dental health of nursery pigs. ( Cassar, G; Farzan, A; Friendship, RM; Tucker, AL, 2011) |
| "The impact of excessive iodine intake on the development of autoimmune thyroiditis (AIT) is still under debate." | 7.80 | Enhanced iodine supplementation alters the immune process in a transgenic mouse model for autoimmune thyroiditis. ( Allelein, S; Bernecker, C; Domröse, A; Ehlers, M; Feldkamp, J; Haase, M; Papewalis, C; Schinner, S; Schott, M; Stenzel, W; Thiel, A; Willenberg, HS, 2014) |
| "We investigated the combined roles of a low-nutrition diet (low levels of protein, iodine, and selenium) and T-2 toxin in bone development and to establish an experimental animal model of Kashin-Beck disease (KBD) that reliably mimics the disease's pathological changes for further study of the pathogenesis and prevention of the disease." | 7.79 | An animal model of Kashin-Beck disease induced by a low-nutrition diet and exposure to T-2 toxin. ( Kang, P; Pei, F; Shen, B; Yang, J; Yao, Y; Zhou, Z, 2013) |
| "A farm trial was conducted to evaluate the effect of in-water iodine on piglet growth, the incidence of diarrhea, and the development of deleterious oral and dental conditions." | 5.15 | Effect of in-water iodine supplementation on weight gain, diarrhea and oral and dental health of nursery pigs. ( Cassar, G; Farzan, A; Friendship, RM; Tucker, AL, 2011) |
| "The impact of excessive iodine intake on the development of autoimmune thyroiditis (AIT) is still under debate." | 3.80 | Enhanced iodine supplementation alters the immune process in a transgenic mouse model for autoimmune thyroiditis. ( Allelein, S; Bernecker, C; Domröse, A; Ehlers, M; Feldkamp, J; Haase, M; Papewalis, C; Schinner, S; Schott, M; Stenzel, W; Thiel, A; Willenberg, HS, 2014) |
| "We investigated the combined roles of a low-nutrition diet (low levels of protein, iodine, and selenium) and T-2 toxin in bone development and to establish an experimental animal model of Kashin-Beck disease (KBD) that reliably mimics the disease's pathological changes for further study of the pathogenesis and prevention of the disease." | 3.79 | An animal model of Kashin-Beck disease induced by a low-nutrition diet and exposure to T-2 toxin. ( Kang, P; Pei, F; Shen, B; Yang, J; Yao, Y; Zhou, Z, 2013) |
| "Iodine concentration was determined in thyroid gland, liver, kidney, muscle, fat, and skin by ICP-MS." | 2.77 | Effect of iodine source and dose on growth and iodine content in tissue and plasma thyroid hormones in fattening pigs. ( Hammerl, S; Li, Q; Mair, C; Schedle, K; Schodl, K; Windisch, W, 2012) |
| "Iodine was determined in the thyroid and in the fractions innards/blood, bones and muscle/fat of four pigs of each group by ICP-MS." | 1.35 | Influence of dietary iodine on the iodine content of pork and the distribution of the trace element in the body. ( Berk, A; Flachowsky, G; Franke, K; Leiterer, M; Schöne, F, 2008) |
| "Ractopamine was fed at the level of 10 mg/kg (as-fed basis) of feed." | 1.33 | Effects of different cereal grains and ractopamine hydrochloride on performance, carcass characteristics, and fat quality in late-finishing pigs. ( Baker, DH; Carr, SN; Ellis, M; Killefer, J; McKeith, FK; Rincker, PJ, 2005) |
| " Higher iodine dosage increased the serum T4 concentration of pigs receiving 75 g rapeseed press cake per kg diet (= 1." | 1.31 | Effects of rapeseed-press cake glucosinolates and iodine on the performance, the thyroid gland and the liver vitamin A status of pigs. ( Bargholz, J; Hartung, H; Leiterer, M; Schöne, F; Tischendorf, F, 2001) |
| "Iodine deficiency was evidenced by increased thyroid weight (26%), reduced urinary iodine excretion (80%), and reduced plasma T4 concentrations (22%)." | 1.29 | Thyroid function and deiodinase activities in rats with marginal iodine deficiency. ( Beynen, AC; Janssen, KP; Kaptein, E; Van Der Heide, D; Visser, TJ, 1994) |
| "Since hypothyroidism has definite and substantial morbidity, these results are of importance to public health and medical personnel for a Bayesian approach to the aetiological diagnosis of hypothyroidism and for ordering specific confirmatory laboratory investigations." | 1.28 | Aetiological profile of overt hypothyroidism in Indian population. ( Agarwal, SK; Jangid, DR; Jangid, V; Ram, BK, 1991) |
| " The 2/3 lower glucosinolate dosage of the LGRSM diet also decreased performance and provoked I deficiency, however significantly later." | 1.28 | [Testing in swine of meal extracted from winter rapeseed with different glucosinolate content with regard to iodine supply. 1. Characterization of rapeseed extraction particles and fattening results]. ( Brautzsch, R; Hennig, A; Lange, R; Lüdke, H; Schöne, F, 1990) |
Research
Studies (29)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 10 (34.48) | 18.2507 |
| 2000's | 4 (13.79) | 29.6817 |
| 2010's | 14 (48.28) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| McGovern, FM | 1 |
| Sweeney, T | 1 |
| Ryan, MT | 1 |
| Lott, S | 1 |
| Campion, FP | 1 |
| Boland, TM | 1 |
| Kang, P | 1 |
| Yao, Y | 1 |
| Yang, J | 2 |
| Shen, B | 2 |
| Zhou, Z | 1 |
| Pei, F | 1 |
| Ehlers, M | 1 |
| Thiel, A | 1 |
| Papewalis, C | 1 |
| Domröse, A | 1 |
| Stenzel, W | 1 |
| Bernecker, C | 1 |
| Haase, M | 1 |
| Allelein, S | 1 |
| Schinner, S | 1 |
| Willenberg, HS | 1 |
| Feldkamp, J | 1 |
| Schott, M | 1 |
| Malek, L | 1 |
| Makrides, M | 1 |
| Zhao, LN | 1 |
| Xu, J | 1 |
| Peng, XL | 1 |
| Tian, LY | 1 |
| Hao, LP | 1 |
| Yang, XF | 1 |
| Ying, CJ | 1 |
| Sun, XF | 1 |
| Soriguer, F | 1 |
| Valdes, S | 1 |
| Morcillo, S | 1 |
| Esteva, I | 1 |
| Almaraz, MC | 1 |
| de Adana, MS | 1 |
| Tapia, MJ | 1 |
| Dominguez, M | 1 |
| Gutierrez-Repiso, C | 1 |
| Rubio-Martin, E | 1 |
| Garrido-Sanchez, L | 1 |
| Perez, V | 1 |
| Garriga, MJ | 1 |
| Rojo-Martinez, G | 1 |
| Garcia-Fuentes, E | 1 |
| Eversmann, T | 1 |
| Li, Q | 1 |
| Mair, C | 1 |
| Schedle, K | 1 |
| Hammerl, S | 1 |
| Schodl, K | 1 |
| Windisch, W | 1 |
| Yao, YF | 1 |
| Pei, FX | 1 |
| Li, XB | 1 |
| Zhou, ZK | 1 |
| Li, L | 1 |
| Kang, PD | 1 |
| Tucker, AL | 1 |
| Farzan, A | 1 |
| Cassar, G | 1 |
| Friendship, RM | 1 |
| Gewa, CA | 1 |
| Leslie, TF | 1 |
| Pawloski, LR | 1 |
| Schöne, F | 3 |
| Tischendorf, F | 1 |
| Leiterer, M | 2 |
| Hartung, H | 1 |
| Bargholz, J | 2 |
| NORDSIEK, FW | 1 |
| Carr, SN | 1 |
| Rincker, PJ | 1 |
| Killefer, J | 1 |
| Baker, DH | 1 |
| Ellis, M | 1 |
| McKeith, FK | 1 |
| Wongsuthavas, S | 1 |
| Terapuntuwat, S | 1 |
| Wongsrikeaw, W | 1 |
| Katawatin, S | 1 |
| Yuangklang, C | 1 |
| Beynen, AC | 2 |
| Franke, K | 1 |
| Berk, A | 1 |
| Flachowsky, G | 1 |
| Comby, F | 1 |
| Lagorce, JF | 1 |
| Buxeraud, J | 1 |
| Raby, C | 1 |
| Janssen, KP | 1 |
| Van Der Heide, D | 1 |
| Visser, TJ | 1 |
| Kaptein, E | 1 |
| Allen, LH | 1 |
| Richter, G | 1 |
| Lemser, A | 1 |
| Wichtel, JJ | 1 |
| Craigie, AL | 1 |
| Freeman, DA | 1 |
| Varela-Alvarez, H | 1 |
| Williamson, NB | 1 |
| Elnour, A | 1 |
| Liedén, S | 1 |
| Bourdoux, P | 1 |
| Eltom, M | 1 |
| Khalid, SA | 1 |
| Hambraeus, L | 1 |
| Paik, IK | 1 |
| Jangid, DR | 1 |
| Agarwal, SK | 1 |
| Jangid, V | 1 |
| Ram, BK | 1 |
| Lange, R | 1 |
| Lüdke, H | 1 |
| Brautzsch, R | 1 |
| Hennig, A | 1 |
| Jenkins, KJ | 1 |
| Hidiroglou, M | 1 |
| Rosenfeld, M | 1 |
| Cunningham, S | 1 |
| Harris, WT | 1 |
| Lapey, A | 1 |
| Regelmann, WE | 1 |
| Sawicki, GS | 1 |
| Southern, KW | 1 |
| Chilvers, M | 1 |
| Higgins, M | 1 |
| Tian, S | 1 |
| Cooke, J | 1 |
| Davies, JC | 1 |
| Seliger, VI | 1 |
| Rodman, D | 1 |
| Van Goor, F | 1 |
| Schmelz, A | 1 |
| Mueller, P | 1 |
| Konstan, MW | 1 |
| Plant, BJ | 1 |
| Elborn, JS | 1 |
| Rodriguez, S | 1 |
| Munck, A | 1 |
| Ahrens, R | 1 |
| Johnson, C | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, 2-Arm, Roll-Over Study to Evaluate the Long-term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation[NCT01946412] | Phase 3 | 33 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Absolute Change From Baseline of Parent Study in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84
BMI = (Weight [in kg]) divided by (Stature [in meters]) ^2. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145). (NCT01946412)
Timeframe: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
| Intervention | Kilogram per square meter (kg/m^2) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n=9, 24) | Absolute Change at Week 12 (n=9, 23) | Absolute Change at Week 24 (n=9, 23) | Absolute Change at Week 36 (n=9, 23) | Absolute Change at Week 48 (n=9, 22) | Absolute Change at Week 60 (n=9, 22) | Absolute Change at Week 72 (n=9, 20) | Absolute Change at Week 84 (n=9, 19) | |
| Ivacaftor 50 mg | 15.74 | 0.03 | 0.31 | 0.15 | -0.31 | -0.12 | -0.38 | -0.16 |
| Ivacaftor 75 mg | 16.06 | 0.09 | -0.12 | 0.09 | -0.13 | -0.06 | 0.09 | 0.28 |
Absolute Change From Baseline of Parent Study in Stature at Week 12, 24, 36, 48, 60, 72 and 84
Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145). (NCT01946412)
Timeframe: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
| Intervention | Centimeters (cm) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n=9, 24) | Absolute Change in Week 12 (n=9, 23) | Absolute Change in Week 24 (n=9, 23) | Absolute Change in Week 36 (n=9, 23) | Absolute Change in Week 48 (n=9, 21) | Absolute Change in Week 60 (n=9, 22) | Absolute Change in Week 72 (n=9, 20) | Absolute Change in Week 84 (n=9, 19) | |
| Ivacaftor 50 mg | 89.1 | 4.6 | 6.0 | 7.8 | 9.7 | 11.0 | 12.5 | 13.6 |
| Ivacaftor 75 mg | 102.3 | 5.4 | 7.7 | 8.8 | 10.4 | 11.6 | 13.4 | 15.0 |
Absolute Change From Baseline of Parent Study in Sweat Chloride at Week 24, 48, 72 and 84
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (>=) 15 microliter was required for determination of sweat chloride. Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145). (NCT01946412)
Timeframe: Baseline (study 108), Week 24, 48, 72 and 84 (study 109)
| Intervention | millimole per liter (mmol/L) (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n=7,22) | Absolute Change at Week 24 (n=6,18) | Absolute Change at Week 48 (n=6,15) | Absolute Change at Week 72 (n=7,14) | Absolute Change at Week 84 (n=6,14) | |
| Ivacaftor 50 mg | 93.1 | -62.1 | -29.3 | -46.4 | -46.5 |
| Ivacaftor 75 mg | 99.6 | -48.5 | -51.8 | -52.9 | -58.1 |
Absolute Change From Baseline of Parent Study in Weight at Week 12, 24, 36, 48, 60, 72 and 84
Baseline was defined as the most recent measurement prior to intake of the first dose of study drug in study 108 Part B (NCT01705145) (NCT01946412)
Timeframe: Baseline (study 108), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
| Intervention | kilogram (kg) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n=9, 24) | Absolute Change at Week 12 (n= 9, 23) | Absolute Change at Week 24 (n=9, 23) | Absolute Change at Week 36 (n=9, 23) | Absolute Change at Week 48 (n=9, 22) | Absolute Change at Week 60 (n=9, 22) | Absolute Change at Week 72 (n=9, 20) | Absolute Change at Week 84 (n=9, 19) | |
| Ivacaftor 50 mg | 12.5 | 1.3 | 2.0 | 2.4 | 2.6 | 3.2 | 3.4 | 4.0 |
| Ivacaftor 75 mg | 16.8 | 1.9 | 2.5 | 3.1 | 3.4 | 4.0 | 4.8 | 5.7 |
Absolute Change From Baseline of Study 109 in Body Mass Index (BMI) at Week 12, 24, 36, 48, 60, 72 and 84
BMI = (Weight [in kg]) divided by (Stature [in meters]) ^2. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412). (NCT01946412)
Timeframe: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
| Intervention | kg/m^2 (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n= 9, 24) | Absolute Change at Week 12 (n= 9, 23) | Absolute Change at Week 24 (n= 9, 23) | Absolute Change at Week 36 (n= 9, 23) | Absolute Change at Week 48 (n= 9, 22) | Absolute Change at Week 60 (n= 9, 22) | Absolute Change at Week 72 (n= 9, 20) | Absolute Change at Week 84 (n= 9, 19) | |
| Ivacaftor 50 mg | 16.07 | -0.30 | -0.02 | -0.18 | -0.64 | -0.45 | -0.71 | -0.49 |
| Ivacaftor 75 mg | 16.33 | -0.16 | -0.36 | -0.16 | -0.35 | -0.29 | -0.21 | -0.01 |
Absolute Change From Baseline of Study 109 in Stature at Week 12, 24, 36, 48, 60, 72 and 84
Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412). (NCT01946412)
Timeframe: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
| Intervention | cm (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n=9, 24) | Absolute Change at Week 12 (n=9, 23) | Absolute Change at Week 24 (n=9, 23) | Absolute Change at Week 36 (n=9, 23) | Absolute Change at Week 48 (n=9, 21) | Absolute Change at Week 60 (n=9, 22) | Absolute Change at Week 72 (n=9, 20) | Absolute Change at Week 84 (n=9, 19) | |
| Ivacaftor 50 mg | 91.7 | 2.0 | 3.4 | 5.2 | 7.2 | 8.4 | 10.0 | 11.1 |
| Ivacaftor 75 mg | 105.8 | 1.8 | 4.1 | 5.2 | 6.8 | 8.0 | 9.8 | 11.4 |
Absolute Change From Baseline of Study 109 in Sweat Chloride at Week 24, 48, 72 and 84
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of >=15 microliter was required for determination of sweat chloride. Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412). (NCT01946412)
Timeframe: Baseline (study 109), Week 24, 48, 72 and 84 (study 109)
| Intervention | mmol/L (Mean) | ||||
|---|---|---|---|---|---|
| Baseline (n= 8,23) | Absolute Change at Week 24 (n=7,18) | Absolute Change at Week 48 (n=7,17) | Absolute Change at Week 72 (n=8,15) | Absolute Change at Week 84 (n=7,16) | |
| Ivacaftor 50 mg | 47.8 | -4.3 | 18.1 | -1.5 | -2.4 |
| Ivacaftor 75 mg | 52.9 | 3.4 | -4.5 | -6.0 | -11.2 |
Absolute Change From Baseline of Study 109 in Weight at Week 12, 24, 36, 48, 60, 72 and 84
Baseline is defined as the most recent measurement prior to intake of the first dose of study drug in study 109 (NCT01946412). (NCT01946412)
Timeframe: Baseline (study 109), Week 12, 24, 36, 48, 60, 72 and 84 (study 109)
| Intervention | Kg (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n= 9, 24) | Absolute Change at Week 12 (n=9, 23) | Absolute Change at Week 24 (n=9, 23) | Absolute Change at Week 36 (n=9, 23) | Absolute Change at Week 48 (n=9, 22) | Absolute Change at Week 60 (n=9, 22) | Absolute Change at Week 72 (n=9, 20) | Absolute Change at Week 84 (n=9, 19) | |
| Ivacaftor 50 mg | 13.5 | 0.3 | 1.0 | 1.4 | 1.6 | 2.2 | 2.4 | 3.0 |
| Ivacaftor 75 mg | 18.3 | 0.4 | 1.0 | 1.6 | 1.9 | 2.5 | 3.3 | 4.2 |
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation was considered treatment-emergent. (NCT01946412)
Timeframe: Day 1 up to Week 97 (for participants who completed study drug dosing); Day 1 up to 24 weeks after the last dose (up to Week 108, for participants who prematurely discontinued study drug dosing)
| Intervention | participants (Number) | |
|---|---|---|
| AEs | SAEs | |
| Ivacaftor 50 mg | 9 | 6 |
| Ivacaftor 75 mg | 24 | 5 |
Reviews
1 review available for iodine and Weight Gain
| Article | Year |
|---|---|
Nutritional influences on linear growth: a general review.
Topics: Body Height; Child; Child Nutrition Disorders; Child, Preschool; Copper; Developing Countries; Diet; | 1994 |
Trials
4 trials available for iodine and Weight Gain
| Article | Year |
|---|---|
Effect of iodine source and dose on growth and iodine content in tissue and plasma thyroid hormones in fattening pigs.
Topics: Animal Husbandry; Animals; Austria; Crosses, Genetic; Diet; Energy Intake; Iodates; Iodine; Kidney; | 2012 |
Effect of in-water iodine supplementation on weight gain, diarrhea and oral and dental health of nursery pigs.
Topics: Animals; Diarrhea; Dietary Supplements; Female; Iodine; Male; Mouth Diseases; Swine; Swine Diseases; | 2011 |
An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).
Topics: Aminophenols; Body Mass Index; Child, Preschool; Chloride Channel Agonists; Cystic Fibrosis; Cystic | 2019 |
Efficacy response in CF patients treated with ivacaftor: post-hoc analysis.
Topics: Adolescent; Adult; Aminophenols; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis Transmembrane Co | 2015 |
Other Studies
24 other studies available for iodine and Weight Gain
| Article | Year |
|---|---|
An investigation into the effects of maternal supplementation with excess iodine on the mechanisms and impacts of reduced IgG absorption in the lamb postpartum.
Topics: Animals; Animals, Newborn; beta 2-Microglobulin; Colostrum; Dietary Supplements; Female; Gene Expres | 2017 |
An animal model of Kashin-Beck disease induced by a low-nutrition diet and exposure to T-2 toxin.
Topics: Animal Nutritional Physiological Phenomena; Animals; Cartilage, Articular; Chondrocytes; Dietary Pro | 2013 |
Enhanced iodine supplementation alters the immune process in a transgenic mouse model for autoimmune thyroiditis.
Topics: Animals; CD8-Positive T-Lymphocytes; Cytokines; Dietary Supplements; Female; Immunity, Cellular; Imm | 2014 |
2.8 Nutrition in pregnancy and lactation.
Topics: Alcohol Drinking; Body Mass Index; Breast Feeding; Caffeine; Calcium, Dietary; Dairy Products; Diet; | 2015 |
Dose and time-dependent hypercholesterolemic effects of iodine excess via TRbeta1-mediated down regulation of hepatic LDLr gene expression.
Topics: Animals; Dose-Response Relationship, Drug; Down-Regulation; Drinking; Eating; Female; Hypercholester | 2010 |
Thyroid hormone levels predict the change in body weight: a prospective study.
Topics: Adiponectin; Adult; Body Weight; Cohort Studies; Female; Follow-Up Studies; Humans; Insulin Resistan | 2011 |
[Hypothyroidism].
Topics: Aged; Algorithms; Fatigue; Female; Humans; Hypothyroidism; Iodine; Pregnancy; Selenium; Thyroid Func | 2011 |
Preventive effects of supplemental selenium and selenium plus iodine on bone and cartilage development in rats fed with diet from Kashin-Beck disease endemic area.
Topics: Animals; Bone Development; Cartilage; Diet; Dietary Supplements; Drug Synergism; Endemic Diseases; F | 2012 |
Geographic distribution and socio-economic determinants of women's nutritional status in Mali households.
Topics: Adult; Anthropometry; Body Mass Index; Breast Feeding; Catchment Area, Health; Contraceptive Agents; | 2013 |
Effects of rapeseed-press cake glucosinolates and iodine on the performance, the thyroid gland and the liver vitamin A status of pigs.
Topics: Animal Feed; Animals; Brassica rapa; Dose-Response Relationship, Drug; Eating; Glucosinolates; Iodin | 2001 |
A goitrogenic rat diet producing normal body weight gain.
Topics: Animals; Body Weight; Diet; Goiter; Ideal Body Weight; Iodine; Nutrition Assessment; Nutritional Sta | 1961 |
Effects of different cereal grains and ractopamine hydrochloride on performance, carcass characteristics, and fat quality in late-finishing pigs.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Animal Feed; Animals; Body Weight; Diet; Edible Grain; | 2005 |
Influence of amount and type of dietary fat on deposition, adipocyte count and iodine number of abdominal fat in broiler chickens.
Topics: Abdominal Fat; Adipocytes; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Body Co | 2008 |
Influence of dietary iodine on the iodine content of pork and the distribution of the trace element in the body.
Topics: Analysis of Variance; Animal Feed; Animals; Deficiency Diseases; Dose-Response Relationship, Drug; F | 2008 |
Antithyroid action of ketoconazole: in-vitro studies and rat in-vivo studies.
Topics: Animals; Antithyroid Agents; In Vitro Techniques; Iodine; Ketoconazole; Lactoperoxidase; Male; Methi | 1994 |
Thyroid function and deiodinase activities in rats with marginal iodine deficiency.
Topics: Animals; Brain; Creatinine; Diet; Eating; Iodide Peroxidase; Iodine; Liver; Male; Organ Size; Rats; | 1994 |
[Rapeseed and rapeseed meal as components in diets of laying hens].
Topics: Animal Feed; Animals; Brassica; Chickens; Diet; Eating; Egg Yolk; Eggs; Fatty Acids; Female; Iodine; | 1996 |
Effect of selenium and lodine supplementation on growth rate and on thyroid and somatotropic function in dairy calves at pasture.
Topics: Animals; Cattle; Female; Growth Hormone; Iodine; Kinetics; Rumen; Selenium; Thyroid Gland; Thyrotrop | 1996 |
Traditional fermentation increases goitrogenic activity in pearl millet.
Topics: Animals; Calcification, Physiologic; Diet; Dietary Proteins; Energy Metabolism; Fermentation; Goiter | 1998 |
Nutritional value of processed rapeseed meal.
Topics: Amino Acids; Ammonia; Animal Feed; Animals; Antithyroid Agents; Brassica; Chickens; Eating; Energy I | 1991 |
Aetiological profile of overt hypothyroidism in Indian population.
Topics: Adult; Female; Humans; Hypothyroidism; India; Iodine; Male; Middle Aged; Postoperative Complications | 1991 |
[Testing in swine of meal extracted from winter rapeseed with different glucosinolate content with regard to iodine supply. 1. Characterization of rapeseed extraction particles and fattening results].
Topics: Animal Feed; Animals; Brassica; Eating; Female; Glucosinolates; Glycine max; Iodine; Male; Swine; We | 1990 |
Effects of elevated iodine in milk replacer on calf performance.
Topics: Animal Feed; Animals; Cattle; Digestion; Eating; Ethylenediamines; Iodine; Male; Thyroid Gland; Tiss | 1990 |
The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.
Topics: Administration, Oral; Adolescent; Aminophenols; Child; Chlorides; Cystic Fibrosis; Cystic Fibrosis T | 2013 |